Clinical trials
Metastatic Hormone-sensitive Prostate Cancer (mHSPC) clinical trials
Below are recruiting metastatic hormone-sensitive prostate cancer (mhspc) clinical trials, each written for real people, not researchers. We’re tracking 28 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07339267RecruitingPhase 1
Safety and dosing study of ASP5541 in Chinese men with metastatic prostate cancer
This study tests a new drug called ASP5541 for Chinese men with prostate cancer that has spread. The drug is given as a shot, and researchers want to see if it is safe and what the right dose might be.
Beijing, Beijing MunicipalityAges 18–85 - NCT07451002Recruiting
Study on Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer
This study looks at how well men with prostate cancer that has spread and is still hormone-sensitive stick to taking the drug apalutamide. It aims to understand real-world use and quality of life.
CaenAges 18 years+ - NCT07572760Recruiting
Power Training for Men With Advanced Prostate Cancer
This study tests whether light-to-moderate strength training exercises can help men with advanced prostate cancer that has spread to bones or lymph nodes. The goal is to see if exercise improves physical strength and quality of life while you continue your cancer medications.
San Vicent del Raspeig, AlicanteAges 50 years+ - NCT06655259RecruitingPhase 2
TURP with standard therapy for metastatic prostate cancer
This trial tests whether adding a surgery called TURP (transurethral resection of the prostate) to the usual hormone therapy and chemotherapy can help men with metastatic prostate cancer that has spread to lymph nodes, bone, or other organs. The surgery helps relieve urinary symptoms and may improve how well the cancer responds to treatment.
Shanghai, Shanghai MunicipalityAges 18–80
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic hormone-sensitive prostate cancer (mhspc)?
- Yes. Clin2 currently lists 28 recruiting metastatic hormone-sensitive prostate cancer (mhspc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic hormone-sensitive prostate cancer (mhspc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic hormone-sensitive prostate cancer (mhspc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hormone Sensitive Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Prostate Cancer Metastatic Disease
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Castration Sensitive Prostate Cancer
- Castrate Sensitive Prostate Cancer
- Metastatic Castration-Resistant Prostate Cancer Patients
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.